Rocky Strollo1, Andreea Soare1, Yeganeh Manon Khazrai1, Antonio Di Mauro1, Andrea Palermo1, Rossella Del Toro1, Sara Fallucca1, Maria Giovanna Belluomo1, Laura Dugo1, Mario Pianesi2, Paolo Pozzilli1,3, Nicola Napoli4,5. 1. Department of Medicine, Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy. 2. International Study Center for Environment, Agriculture, Food, Health and Economics, Tolentino, Italy. 3. Centre for Immunobiology, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK. 4. Department of Medicine, Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy. n.napoli@unicampus.it. 5. Department of Medicine, Division of Bone and Mineral Diseases, Washington University in St. Louis, St. Louis, MO, USA. n.napoli@unicampus.it.
Abstract
BACKGROUND:Sclerostin has been directly related to bone turnover increase in dietary-induced weight loss in non-diabetics. This has not been studied in type 2 diabetes, a condition characterized by increased circulating sclerostin and impaired bone turnover. PURPOSE: To study the effect of dietary weight loss and quality of the dietary intervention on changes of sclerostin and bone turnover markers in type 2 diabetes. METHODS: This was a post-hoc analysis of the MADIAB trial, a 21-day randomized controlled trial on overweight/obese type 2 diabetes patients. Patients were randomly assigned 1:1 to the Ma-Pi2 macrobiotic diet or a control diet based on dietary guidelines for type 2 diabetes. Serum sclerostin and circulating markers of bone resorption and formation (P1NP) were measured by enzyme linked immunosorbent assay in 40 subjects (1:1) at baseline and after 21 days treatment. RESULTS: Both Ma-Pi2 and the control diet groups had significant decreases in body weight (6.0 ± 0.2 vs. 3.2 ± 0.1 %, p < 0.001). Sclerostin increased significantly in the two groups (all p < 0.001) but Ma-Pi2 diet group experienced a greater increase in sclerostin (34.5 vs. 15 %; p = 0.024). Serum circulating markers of bone resorption increased in the two groups (all p < 0.001); circulating markers of bone resorption at the end of the treatment tended to be higher in Ma-Pi2 diet than the control diet group (p = 0.06). P1NP did not change significantly in the two group compared to baseline. Sclerostin changes were related to body mass index reduction (r = -0.37; p = 0.02). CONCLUSIONS: Diet-induced weight loss may induce significant and rapid changes in bone turnover and sclerostin levels. These changes may further impair bone health in subjects with type 2 diabetes.
RCT Entities:
BACKGROUND:Sclerostin has been directly related to bone turnover increase in dietary-induced weight loss in non-diabetics. This has not been studied in type 2 diabetes, a condition characterized by increased circulating sclerostin and impaired bone turnover. PURPOSE: To study the effect of dietary weight loss and quality of the dietary intervention on changes of sclerostin and bone turnover markers in type 2 diabetes. METHODS: This was a post-hoc analysis of the MADIAB trial, a 21-day randomized controlled trial on overweight/obese type 2 diabetespatients. Patients were randomly assigned 1:1 to the Ma-Pi2 macrobiotic diet or a control diet based on dietary guidelines for type 2 diabetes. Serum sclerostin and circulating markers of bone resorption and formation (P1NP) were measured by enzyme linked immunosorbent assay in 40 subjects (1:1) at baseline and after 21 days treatment. RESULTS: Both Ma-Pi2 and the control diet groups had significant decreases in body weight (6.0 ± 0.2 vs. 3.2 ± 0.1 %, p < 0.001). Sclerostin increased significantly in the two groups (all p < 0.001) but Ma-Pi2 diet group experienced a greater increase in sclerostin (34.5 vs. 15 %; p = 0.024). Serum circulating markers of bone resorption increased in the two groups (all p < 0.001); circulating markers of bone resorption at the end of the treatment tended to be higher in Ma-Pi2 diet than the control diet group (p = 0.06). P1NP did not change significantly in the two group compared to baseline. Sclerostin changes were related to body mass index reduction (r = -0.37; p = 0.02). CONCLUSIONS: Diet-induced weight loss may induce significant and rapid changes in bone turnover and sclerostin levels. These changes may further impair bone health in subjects with type 2 diabetes.
Entities:
Keywords:
Bone turnover; Macrobiotic Ma-Pi2 diet; Type 2 diabetes
Authors: S A Polyzos; A D Anastasilakis; C Bratengeier; W Woloszczuk; A Papatheodorou; E Terpos Journal: Osteoporos Int Date: 2011-01-11 Impact factor: 4.507
Authors: Christian Muschitz; Roland Kocijan; Christina Marterer; Arastoo Rahbar Nia; Gabriela Katharina Muschitz; Heinrich Resch; Peter Pietschmann Journal: J Clin Endocrinol Metab Date: 2014-12-09 Impact factor: 5.958
Authors: Alexander G Robling; Paul J Niziolek; Lee A Baldridge; Keith W Condon; Matthew R Allen; Imranul Alam; Sara M Mantila; Jelica Gluhak-Heinrich; Teresita M Bellido; Stephen E Harris; Charles H Turner Journal: J Biol Chem Date: 2007-12-17 Impact factor: 5.157
Authors: Andreea Soare; Rossella Del Toro; Elena Roncella; Yeganeh Manon Khazrai; Silvia Angeletti; Laura Dugo; Sara Fallucca; Lucia Fontana; Maria Altomare; Valeria Formisano; Francesca Capata; Rosaria Gesuita; Silvia Manfrini; Francesco Fallucca; Mario Pianesi; Paolo Pozzilli Journal: BMJ Open Diabetes Res Care Date: 2015-03-26
Authors: Katarzyna Wyskida; Grzegorz Franik; Aleksander Jerzy Owczarek; Piotr Choręza; Piotr Kocełak; Paweł Madej; Jerzy Chudek; Magdalena Olszanecka-Glinianowicz Journal: Arch Gynecol Obstet Date: 2020-06-26 Impact factor: 2.344